Abstract 152P
Background
Adenosine accumulates in the tumor microenvironment due to abnormal tumor metabolism and hypoxia. It binds to A2A and A2B receptors on immune cells and impairs their activation and cytotoxic ability, helping cancers to evade the immune system and resist cancer therapies. Adenosine receptor antagonists that act in pathological concentrations of adenosine can rescue T cell and innate immune suppression and improve the efficacy of existing treatments.
Methods
We used structure-guided medicinal chemistry to design adenosine antagonists and measured how well they bind to A2A and A2B receptors in cells using HTRF and Tag-lite technology. Their ability to block adenosine’s effect on primary immune cells was monitored by measuring CREB phosphorylation and cytokine production. In vitro coculture assays and syngeneic mouse models were used to check the effect of immune response and tumor growth. We also used a patient-derived ex vivo tumor platform to demonstrate clinical translatability.
Results
BWC2094 is a potent A2A receptor antagonist, while BWC2562 is a potent A2A/A2B dual antagonist in a high adenosine environment. They selectively bind A2A at picomolar concentrations and had >50-fold selectivity over A1 and A3 receptors. They reduced the phosphorylation of CREB and restored the production of cytokines, such as IL2, TNFα and IFNγ in adenosine-suppressed immune cells. The lead compounds exhibited a synergistic effect with standard of care drugs in co-culture assays of tumor cells and PBMC. Both, BWC2094 and BWC2562 demonstrated good oral bioavailability in rodents (>25 %F) and dogs (>50 %F) and are well tolerated for 14 days in rat acute toxicity study. At a dose of 3mg/kg, they reduce the tumor volume as monotherapy and enhanced the anti-tumor effects of anti-PD1/PDL1 and CTLA4 in CT26, MC38, and MCA205 murine tumor models. In a patient-derived ex vivo tumor model, Precision immunotherapy using Complementary approaches in Systems Oncology (PiCaSO), they reduced tumor density, decreased Ki67 expression and increased apoptosis/necrosis.
Conclusions
BWC2094 and BWC2562 can block the immunosuppressive effects of adenosine and improve the effectiveness of existing therapies in oncology.
Legal entity responsible for the study
The authors.
Funding
Bugworks Research Inc.
Disclosure
N. Katagihallimath, R. Nandishaiah, S. Sharma, S. Venkatesan, R. Rao, N. Bharatham, M. Gupta, D. Kundu, H. Kaushik Kotakonda, R. Ramalingam Kalainesan, S. Reddy, B. Tewary, L. Maitreyi, B. Venkatraman, S. V Rekha Sody, B. Majumder: Financial Interests, Personal and Institutional, Stocks/Shares: Bugworks. S. Datta, S.Hameed: Financial Interests, Personal and Institutional, Stocks or ownership: Bugworks. All other authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display